News

For the year ended December 31, 2004, earnings per share were down 9% compared to last year, although Q4 figures showed a 6% increase, which will, no doubt,

“We believe this patent, which combines Akesis’ unique formula of anti-diabetic trace minerals with the widely prescribed sulfonylurea class of medications is an important step in our mission

Although Shire is complying with this request to suspend sales, the company strongly disagrees with the conclusions drawn by Health Canada following the product’s labeling update and is

Rhodia Pharma Solutions will be responsible for the manufacture of active pharmaceutical ingredients used in the production of various formulations of zileuton, including Zyflo filmtab (zileuton tablets), which

Bivatuzumab mertansine consists of the Boehringer Ingelheim anti-CD44v6 antibody, bivatuzumab, and ImmunoGen’s DM1 cytotoxic agent, mertansine. Development of bivatuzumab mertansine was discontinued due to the occurrence of skin

Biodefense and Emerging Infections (BEI) Resources was established by the National Institute of Allergy and Infectious Diseases (NIAID) to acquire, authenticate, and produce reagents for scientists to carry

The patented molecule, now called CXS299, is a platinum (IV) anticancer compound invented by professors in the department of experimental therapeutics at MD Anderson Cancer Center. CXS299 is

The projects will range from discovery to developmental stage programs and reach across multiple research sites of Pfizer’s Global R&D organization. Financial terms of the transaction include an

The formulations covered by the patent are applications of the company’s proprietary RapidMist drug delivery technology and are designed to deliver pain relief medications such as morphine and